https://trial.medpath.com/news/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7